Research programme: osteoarthritis therapeutics - ProStrakan/TiGenix

Drug Profile

Research programme: osteoarthritis therapeutics - ProStrakan/TiGenix

Alternative Names: BMP activators - ProStrakan/TiGenix; Bone morphogenetic protein activators - ProStrakan/TiGenix

Latest Information Update: 19 Sep 2007

Price : $50

At a glance

  • Originator ProStrakan; TiGenix
  • Class Small molecules
  • Mechanism of Action Bone morphogenetic protein activators; Osteoblast stimulants; Osteogenesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued Osteoarthritis

Most Recent Events

  • 19 Apr 2006 Preclinical development is ongoing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top